India Artesunate Market to be grow by CAGR of 6.01% through 2030
Growing prevalence of malaria is expected to drive the
India Artesunate Market in the forecast period 2026-2030
According to TechSci Research report, “India
Artesunate Market - By Region, Competition, Forecast
& Opportunities, 2030F”, India Artesunate
Market was valued at USD 96.54 Million in 2024 and is expected to reach USD 135.91
Million by 2030, growing with a CAGR of 6.01% in the forecast period.
The
India Artesunate market is a vital component of the country’s healthcare and
pharmaceutical landscape, given its crucial role in combating malaria—a disease
that continues to affect large segments of the population, particularly in
high-burden states. Artesunate, a water-soluble derivative of artemisinin, is
the gold standard for treating severe malaria, especially Plasmodium
falciparum infections, which account for the majority of malaria-related
complications and deaths in India. The demand for artesunate has remained
strong due to its fast oover half of the country's malaria cases, leading to a concentrated demand for
both injectable and oral artesunate formulations.
The Indian government has prioritized malaria control and elimination through initiatives like the National Vector Borne Disease Control Programme (NVBDCP), the National Strategic Plan (NSP) for Malaria Elimination, and state-level programs focusing on diagnosis, treatment, and vector control. These programs procure significant quantities of artesunate through large-scale tenders, making government procurement the primary sales channel for most manufacturers. As a result, the market is highly dependent on the public sector, with limited penetration in the private healthcare space, particularly in rural and semi-urban areas.
In terms of formulation trends, oral artesunate tablets dominate in volume due to ease of use, affordability, and wide deployment in outpatient and community health settings. However, injectable artesunate is gaining prominence for hospital-based treatment of severe and complicated malaria cases. Hospitals account for a growing share of injectable use, driven by clinical protocols that mandate rapid parasite clearance in life-threatening situations. The market has also seen increasing adoption of combination therapies, such as artesunate with mefloquine or amodiaquine, to enhance efficacy and reduce the risk of resistance.
India’s strength in pharmaceutical manufacturing plays a crucial role in this market. Several domestic companies produce artesunate in bulk for national consumption and export to other malaria-endemic countries in Asia and Africa. The government's Production-Linked Incentive (PLI) scheme and promotion of bulk drug parks aim to boost local production of key APIs, including those used in antimalarial drugs. With India being one of the world’s largest generic medicine exporters, artesunate produced in India is a cost-effective solution for global health organizations and developing countries battling malaria.
However, the market faces several challenges. Rising artemisinin resistance, particularly in parts of northeastern India, poses a long-term threat to artesunate’s efficacy. Regulatory complexities and quality assurance requirements add to the burden for smaller manufacturers, while counterfeit and substandard products compromise both patient safety and treatment outcomes. Supply chain disruptions, especially in remote tribal areas, can lead to stockouts and treatment delays. The private sector uptake remains limited, as most severe cases are treated in public hospitals under government schemes, reducing opportunities for retail distribution. Despite these constraints, the market is gradually evolving. The growth of digital health platforms and online pharmacies is opening new distribution channels for artesunate, particularly in urban and semi-urban areas. There is also a growing focus on pharmacovigilance, quality certification (such as WHO prequalification), and development of newer fixed-dose combination therapies that could increase treatment compliance and reduce resistance. As India continues its push toward malaria elimination by 2030, sustained investment, policy support, and innovation in artesunate manufacturing and distribution will be key to unlocking the full potential of this market.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "India Artesunate Market ”
The India Artesunate Market is segmented into source, form,
route of administration, distribution channel, application, regional
distribution, and company.
Based on route of administration, in the Indian
artesunate market, oral formulations are dominant over intravenous (IV)
formulations, primarily due to their widespread use in treating uncomplicated
malaria and ease of distribution through public health systems. Oral
artesunate, typically administered in tablet form, is used extensively in
outpatient and community-based programs, especially in rural and semi-urban
areas where access to hospitals or trained medical staff is limited. These
tablets are cost-effective, easy to store, and do not require specialized
administration, making them suitable for large-scale public health campaigns
and home-based care.
Intravenous artesunate, on the other hand, is reserved
for severe and complicated malaria cases, which represent a smaller proportion
of the total malaria burden. While IV artesunate is critical for emergency
treatment due to its rapid action, it requires clinical infrastructure, trained
personnel, and cold chain logistics, limiting its use to hospital settings. As
a result, volume-wise, oral artesunate dominates the market. However, in terms
of value, the IV segment is growing steadily, driven by increasing
hospitalization rates and updated clinical protocols favoring IV artesunate for
severe malaria. Despite this growth, the overall dominance remains with oral
formulations due to their scale of usage across India’s extensive
malaria-endemic regions.
Based on distribution
channel, In the Indian artesunate market, offline
distribution channels continue to dominate over online platforms, largely due
to the nature of the product, the structure of India’s healthcare system, and
the demographics of malaria-affected regions. Artesunate, especially in its
injectable form, is a prescription-based medication used in the treatment of
moderate to severe malaria, which is predominantly managed through government
hospitals, public health centers, and offline retail pharmacies.
Over 80% of malaria cases in India are diagnosed and
treated in public healthcare settings, where offline procurement and
administration are the norm. Most rural and tribal populations—who account for
the majority of malaria burden—have limited internet access and rely on
physical pharmacies and healthcare centers. Offline channels are also preferred
for ensuring proper medical supervision, particularly for injectable
formulations that require trained professionals for administration. Online
pharmacies, though growing rapidly in urban areas, still account for a
relatively small share of overall pharmaceutical sales, especially for
prescription drugs like artesunate. Their reach in malaria-endemic zones is
limited due to logistical challenges and regulatory constraints on dispensing
high-risk drugs online. While online platforms are expanding in urban markets
and may grow in relevance over time, offline channels remain the dominant mode
of distribution for artesunate in India due to accessibility, regulatory
control, and the need for professional oversight in malaria treatment.
Major companies operating in India
Artesunate Market are:
- Solara Active Pharma Sciences Limited
- Gonane Pharma
- Cipla Limited
- Mangalam Drugs & Organics Limited
- Nishchem International Pvt. Ltd.
- Vaishali Pharma Limited
- Vital Laboratories Private Limited
- Actiza Pharmaceutical Pvt. Ltd
- Systacare Remedies
- Prism Industries Ltd.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The India Artesunate market is a vital segment of the
country’s pharmaceutical and public health landscape, primarily driven by the
treatment of *Plasmodium falciparum* malaria. With high disease prevalence in
eastern and northeastern states, the demand for both oral and injectable
artesunate remains strong. Government-led programs supply the majority of the
market through large-scale tenders, ensuring widespread access in
malaria-endemic areas. While oral tablets dominate in volume due to their
convenience and affordability, injectables are gaining traction in hospital
settings for severe cases. Growing concerns over drug resistance and regional
outbreaks continue to sustain market relevance and drive public health
investments”, said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“India Artesunate Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet v/s Injection), By Route of Administration (Oral v/s Intravenous), By Application (Malaria, Parasitic Infections, COVID-19, Others), By Distribution Channel (Online v/s Offline), By Company, By Region, Forecast & Opportunities, 2020-2030”,
has evaluated the future growth potential of India Artesunate Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in India Artesunate
Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com